Toggle menu

Code Red

Start date:
April 2014
End date:
December 2018
Co-ordinated by:
Matthew Reed, Alison Glover

Transfusion and Laboratory support in Trauma Group Code Red Audit

Aim

The aim of the Code Red audit is to monitor and optimise the transfusion support given to patients following major trauma in Scotland

Objective

The primary objective is to optimise the transfusion support given to patients following major trauma in Scotland, including the delivery of laboratory services and transfusion support in both the pre-hospital and hospital setting along with the introduction of novel services and approaches.

Design

A standardised data collection form (DCF) was designed and agreed by the Transfusion and Laboratory Support in Trauma Group (TLSTG). Page one of the DCF contains patient information and a unique national code red audit number. Pages 2-4 of the DCF contain anonymised data which will be sent to Alison Glover to enter onto a secure database. Once piloting, this anonymised data will be entered directly onto a web based database (REDcap).

Ethics opinion was obtained from the Lothian Regional Ethics Committee Scientific Advisor and the project was deemed a service evaluation/audit and not therefore requiring full ethics submission. The Caldicott guardian for NHS Lothian has approved the use of the REDcap secure database. Funding for use of the REDcap database was secured from SNBTS

All data is owned by the NHS. Matthew Reed and Alison Glover will maintain the database and act as guardians for the data. The project will initially last 2 years until 30th September 2016 however it is anticipated that the project will be an ongoing one. Data collection is currently underway including retrospective data collection from the introduction of the Code Red protocol at each participating hospital.

Who is Involved

Scotland’s main trauma receiving hospitals have agreed to input data into the National Code Red audit and a clinical and transfusion lead has been identified for each centre.

Local PI

Matthew Reed,Research Team – Members of the Transfusion and Laboratory support in Trauma Group

Eligibility criteria

Scotland’s main trauma receiving hospitals have agreed to input data into the National Code Red audit

 

Publications

  • Reed MJ, Glover A, Byrne L, Donald M, McMahon N, Hughes N, Littlewood NK, Garrett J, Innes C, McGarvey M, E Hazra E, Rawlinson PSM on behalf of the Scottish Transfusion and Laboratory Support in Trauma Group. Experience of implementing a National Code Red bleeding protocol in Scotland. Injury, Int. J. Care Injured2017; 48: 41–46

Chief Investigator

Dr Matt Reed

Director of EMERGE, Consultant, NRS Career Research Fellow & Honorary Reader in Emergency Medicine

Local PI

Dr Matt Reed

Director of EMERGE, Consultant, NRS Career Research Fellow & Honorary Reader in Emergency Medicine

Research Team

Alison Glover

Lead Research Nurse (BTS)

More EMERGE Trials

TARGET CTCA is a joint venture between EMERGE and the cardiology research team aiming to recruit patients with suspected ACS across NHS Lothian and NHS Greater Glasgow and Clyde. The study aims to recruit 2270 participants. For further information, please contact the EMERGE team.

Read more

TARGET-CTCA Trial

People who develop an Acute Kidney Injury (AKI) often have a poor prognosis and many go on to develop chronic kidney disease (CKD). The recognition that AKI and CKD are linked is recent and the molecular pathways that control the transition from acute injury to chronic disease are not well defined. Currently there are no specific treatments that reduce the risk of progressing to CKD after AKI.

Preliminary investigations (not yet published) suggest that AKI causes sustained activation of the endothelin (ET) system to the long-term detriment of renal and systemic haemodynamic function. These pilot data form the basis of our project that seeks to determine whether the ET system is active in patients with AKI and, thus, represents a potential target for therapeutic intervention.

KRAKIL aims to recruit altogether 100 patients from across the emergency department, acute medical unit and inpatient wards at the Royal Infirmary. 50 of which with AKI’s and 50 matched controls with normal kidney function. We will monitor their bloods and urine for 90 days and compare the data from between the two groups.

Read more

KRAKIL Study

Diagnostics devices play an important part in the clinical assessment of a patient’s health and treatment. The purpose of the study is the evaluation of a new diagnostic platform developed by LumiraDx. The evaluation is focused around various biomarkers useful in the emergency settings.

Read more

NOVEL Study

Collection of venous and capillary blood samples for the evaluation of new diagnostic devices for cardiovascular conditions